The analysis results of TCGA-LUAD and TCGA-LUSC cohorts revealed that the total anticancer immunity score, cancer antigen presentation score, priming and activation score, T cell (CD4 + and CD8 + T cell) recruiting score, and immune cell infiltration score were significantly higher in high RILPL2 expression groups, which suggested the NSCLC patients expressing high levels of RILPL2 might experience an improved anticancer immune response. The gene discussed is CD4; the disease is cancer.